PITTSBURGH--(BUSINESS WIRE)--Precision Therapeutics announced today that findings from a clinical study supporting performance of the ChemoFx® drug response marker as a predictive marker have been released by British Journal of Cancer, an elite professional medical journal of Cancer Research UK. This key publication was developed in cooperation with physicians and researchers from the Mayo Clinic, MD Anderson Cancer Center, The Western Pennsylvania Hospital and Washington University School of Medicine, and answers the important clinical question of whether ChemoFx is predictive of treatment-specific outcomes in ovarian cancer patients.
Help employers find you! Check out all the jobs and post your resume.
